Nanobiotix (NBTX) analyst forecast and price target
Analyst forecast
Consensus of 7 analyst ratings
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Leerink Partners | Maintained | Outperform | $46.00 from $37.00 | Jun 4, 2026 |
| UBS | Maintained | Neutral | $30.00 from $3.50 | May 1, 2026 |
| Guggenheim | Maintained | Buy | $36.00 from $26.00 | Apr 2, 2026 |
| Guggenheim | Maintained | Buy | $26.00 from $8.00 | Feb 6, 2026 |
| Guggenheim | Maintained | Buy | $8.00 from $12.00 | Apr 4, 2025 |
| Guggenheim | Initiated Coverage | Buy | $12.00 | Aug 28, 2024 |
| Leerink Partners | Initiated Coverage | Outperform | $11.00 | Dec 8, 2023 |
Frequently asked questions
Is NBTX a buy, sell, or hold?
Analysts covering Nanobiotix currently average a Buy rating: 7 buy, 0 hold and 0 sell, from 7 analysts. Ratings reflect analyst opinion, not investment advice.
What is the latest analyst rating on NBTX?
On Jun 4, 2026, Leerink Partners maintained Nanobiotix at Outperform with a price target of $46.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.